MicroRNA-152 Targets Phosphatase and Tensin Homolog to Inhibit Apoptosis and Promote Cell Migration of Nasopharyngeal Carcinoma Cells

Huang, Shunde; Li, Xiaohua; Zhu, Haotu

doi:10.12659/msm.898110

Cited by 21 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-152, a member of miR-148/152 family, has been reported to be downregulated, and to function as a tumor suppressive miRNA in majority types of cancer (11)(12)(13)(14)(15)(16). In contrast, in neuroblastoma and nasopharyngeal carcinoma, miR-152 expression was upregulated, suggesting that miR-152 acts as an oncogene miRNA (21,22). These results suggested that miR-152 could serve as either oncogene or tumor suppressor in different types of cancer.…”

Section: Discussionmentioning

confidence: 99%

Function of miR‑152 as tumor suppressor in oral squamous cell carcinoma cells by targeting c‑MET

Wang³

et al. 2017

Oncol Rep

View full text Add to dashboard Cite

MicroRNA‑152 (miR‑152) has been reported to be involved in tumor development and progression in multiple cancers. However, the expression level, biological function and regulatory mechanisms of miR‑152 in oral squamous cell carcinoma cells (OSCC) remain unclear. The aims of this study were therefore to investigate the role of miR‑152 in OSCC and the relevant mechanism. It was found that miR‑152 was downregulated in OSCC cell lines and tissues, and that decreased miR‑152 was closely associated with lymph node metastasis, and patient survival rate. In vitro restoration of miR‑152 significantly repressed cell proliferation, colony formation, migration and invasion of OSCC cells. Notably, cellular-mesenchymal to epithelial transition factor (c‑MET) and its downstream signaling pathway (PI3K/AKT) was downregulated in OSCC cells by miR‑152 through direct interactions with its 3' untranslated region. Restoring c‑MET expression attenuated miR‑152-induced inhibitory effects in OSCC cells. In vivo study confirmed that restoration of miR‑152 suppressed tumor growth in xenograft nude mice by repressing c‑MET. In summary, the present study highlight miR‑152 as a tumor suppressor in OSCC through direct targeting c‑MET, rendering miR‑152 a promising therapeutic target for oral squamous cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Function of miR‑152 as tumor suppressor in oral squamous cell carcinoma cells by targeting c‑MET

Wang³

et al. 2017

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…In addition, the suppression of miR-152 biogenesis increases cisplatin resistance in epithelial ovarian cancer (55). However, the overexpression of miR-152 increases cisplatin resistance and proliferation of nasopharyngeal carcinoma cells (56), while the overexpression of miR-762 stimulates the development of various tumors, including ovarian (57) and breast cancer (58). Conversely, the expression of miR-762 (in combination with other miRNAs) leads to the apoptosis of breast cancer cells (59).…”

Section: Discussionmentioning

confidence: 99%

A putative competing endogenous RNA network in cisplatin‑resistant lung adenocarcinoma cells identifying potentially rewarding research targets

Huang

Wei

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) is the most common type of non-small cell lung cancer and has a poor 5 year survival rate (<10%). Cisplatin is one of the most effective chemotherapeutic treatments for LUAD, even though it is of limited overall utility due to acquired drug resistance. To identify possible genetic targets for the mitigation of cisplatin resistance, gene expression data from cisplatin-resistant cell lines were integrated with patient information. Expression data for cisplatin-resistant and cisplatin-sensitive A549 cell lines were obtained from the Gene Expression Omnibus database, while LUAD patient data was obtained from The Cancer Genome Atlas (TCGA) database. Differentially expressed mRNAs (DEmRNAs), microRNAs (DEmiRNAs) and long non-coding RNAs (DElncRNAs) were identified between the cisplatin-sensitive and cisplatin-resistant cells. Using the TCGA patient data, 33 DEmRNAs associated with survival were identified. A total of 74 DElncRNAs co-expressed with the survival-associated DEmRNAs, and 11 DEmiRNAs that regulated the survival-associated DEmRNAs, were also identified. A competing endogenous RNA (ceRNA) network was constructed based on the aforementioned results, which included 17 survival-associated DEmRNAs, 9 DEmiRNAs and 16 DElncRNAs. This network revealed 8 ceRNA pathway axes possibly associated with cisplatin resistance in A549 cells. Specifically, the network suggested that the lncRNAs HOXD-AS2, LINC01123 and FIRRE may act as ceRNAs to increase cisplatin resistance in human LUAD cells. Therefore, it was speculated that these lncRNAs represent potentially rewarding research targets.

show abstract

“…The present study assessed the potential mechanism by which increased miR-152 levels modulates the malignant progression of cervical cancer. It has been suggested that the phosphatase and tensin homolog (PTEN), a tumor suppressor, is decreased in patients with nasopharyngeal carcinoma (NPC) and is associated with the pathological grade and clinical stage of NPC (36). It has been demonstrated that the reduced expression of PTEN in patients with NPC may be associated with the upregulation of miR-152, thereby inhibiting cell apoptosis and enhancing cancer cell proliferation and migration during NPC development (36).…”

Section: Discussionmentioning

confidence: 99%

“…It has been suggested that the phosphatase and tensin homolog (PTEN), a tumor suppressor, is decreased in patients with nasopharyngeal carcinoma (NPC) and is associated with the pathological grade and clinical stage of NPC (36). It has been demonstrated that the reduced expression of PTEN in patients with NPC may be associated with the upregulation of miR-152, thereby inhibiting cell apoptosis and enhancing cancer cell proliferation and migration during NPC development (36). Similarly, the results of the present study indicated that increased miR-152 levels are identified in patients with CIN and patients with cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

miR‑152 may function as an early diagnostic and prognostic biomarker in patients with cervical intraepithelial neoplasia and patients with cervical cancer

Yang

Zhang

2019

Oncol Lett

View full text Add to dashboard Cite

Previous studies have demonstrated that circulating miRNAs are effective biomarkers of various types of cancer. It has also been indicated that miR-152 is upregulated in cervical cancer. However, whether miR-152 may be used as an early detection method for patients with cervical cancer is yet to be elucidated. The results of the current study demonstrated that miR-152 levels were the lowest in healthy controls, high in patients with cervical intraepithelial neoplasia (CIN), and the highest in patients with cervical cancer. Furthermore, miR-152 levels in peripheral blood were higher in patients with high-grade CIN compared with those with low-grade CIN. It was also demonstrated that miR-152 levels increased as the clinical stage of cervical cancer advanced. Compared with healthy controls, squamous cell carcinoma antigen (SSC-Ag) levels were significantly higher in patients with cervical cancer. However, no significant differences were identified in patients with CIN, indicating that SCC-Ag could not be used for the early detection of CIN. In contrast, miR-152 was elevated along with SCC-Ag in patients with CIN and cervical cancer. Receiver operating characteristic (ROC) analysis demonstrated that miR-152 preferentially distinguished patients with CIN (95% confidence interval, 0.688-0.973; P<0.001) and patients with cervical cancer (95% confidence interval, 0.817-0.996; P<0.001) from healthy controls. Additionally, miR-152 levels were markedly reduced in patients with cervical cancer who received chemotherapy (28 patients) or chemotherapy and radiation therapy (22 patients). In conclusion, the level of miR-153 in peripheral blood may be utilized as an effective biomarker for the early detection of cervical cancer, thus decreasing the requirement for invasive cervical biopsies. Furthermore, it may be utilized to predict the most effective form of treatment for patients with cervical cancer.

show abstract

MicroRNA-152 Targets Phosphatase and Tensin Homolog to Inhibit Apoptosis and Promote Cell Migration of Nasopharyngeal Carcinoma Cells

Cited by 21 publications

References 33 publications

Function of miR‑152 as tumor suppressor in oral squamous cell carcinoma cells by targeting c‑MET

Function of miR‑152 as tumor suppressor in oral squamous cell carcinoma cells by targeting c‑MET

A putative competing endogenous RNA network in cisplatin‑resistant lung adenocarcinoma cells identifying potentially rewarding research targets

miR‑152 may function as an early diagnostic and prognostic biomarker in patients with cervical intraepithelial neoplasia and patients with cervical cancer

Contact Info

Product

Resources

About